European Neuropsychopharmacology最新文献

筛选
英文 中文
Environmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists 环境意识心理药物疗法:给精神科医生的实践建议。
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-12 DOI: 10.1016/j.euroneuro.2024.10.003
Jurjen J. Luykx , Caroline T.A. Moermond , Lisa Page , Unax Lertxundi , Christiaan H. Vinkers
{"title":"Environmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists","authors":"Jurjen J. Luykx ,&nbsp;Caroline T.A. Moermond ,&nbsp;Lisa Page ,&nbsp;Unax Lertxundi ,&nbsp;Christiaan H. Vinkers","doi":"10.1016/j.euroneuro.2024.10.003","DOIUrl":"10.1016/j.euroneuro.2024.10.003","url":null,"abstract":"<div><div>Despite the multifaceted negative influences of psychotropic medications on the environment, an overview of such effects and of actions to curtail them is currently lacking. We therefore summarized the most relevant literature on what we refer to as Environmentally Conscious Psychopharmacotherapy (ECP), i.e., prescribing the most appropriate psychotropic medications for patients while at the same time considering the wellbeing of the planet. In our literature appraisal we identified viable actions at the levels of industry, physicians, pharmacists, patients, and policymakers that can reduce the environmental hazards associated with psychotropics. We divided these actions into the following categories: careful treatment selection, curtailing overprescribing, adequate disposal of medication by users, and transparent reporting of environmental risk. For each of these categories, we give examples of practices are in line with ECP, which in turn has the potential to reduce the impact of psychotropic medication prescribing practices on the environment. We note that many such practices result in co-benefits for patients, prescribers and the environment. On the other hand, evidence on environmental impact is lacking for several factors related to these medications, e.g., geographical region of manufacturing, duration of use, pharmacological vs. non-pharmaceutical treatment options, and ecotoxicological data. We conclude that general as well as disorder-specific considerations for clinicians prescribing psychotropics already carry the potential to limit the environmental burden associated with these agents. Future research aimed at filling the knowledge gaps we identified is likely to substantially advance ECP in the near future.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 71-76"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fetal Fentanyl Syndrome – Only the “tip of the iceberg”? 胎儿芬太尼综合征--只是 "冰山一角"?
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-08 DOI: 10.1016/j.euroneuro.2024.10.011
Károly Mirnics
{"title":"Fetal Fentanyl Syndrome – Only the “tip of the iceberg”?","authors":"Károly Mirnics","doi":"10.1016/j.euroneuro.2024.10.011","DOIUrl":"10.1016/j.euroneuro.2024.10.011","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 69-70"},"PeriodicalIF":6.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders 脑源性细胞外囊泡的 microRNA 图谱:在开发精神疾病药效学生物标记物方面迈出充满希望的一步
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.002
Mojtaba Oraki Kohshour , Urs Heilbronner , Thorsten Mueller , Moritz Rossner , Sergi Papiol , Thomas G. Schulze
{"title":"The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders","authors":"Mojtaba Oraki Kohshour ,&nbsp;Urs Heilbronner ,&nbsp;Thorsten Mueller ,&nbsp;Moritz Rossner ,&nbsp;Sergi Papiol ,&nbsp;Thomas G. Schulze","doi":"10.1016/j.euroneuro.2024.10.002","DOIUrl":"10.1016/j.euroneuro.2024.10.002","url":null,"abstract":"<div><div>MicroRNAs (miRNAs) have the potential to affect drug metabolism, and some drugs affect cellular miRNA expression. miRNAs are found inside extracellular vesicles (EVs), and the profile of these EV-miRNAs can change across different diseases and disease states. Consequently, in recent years EV-miRNAs have attracted increasing attention as possible non-invasive biomarkers. For example, analyzing the miRNA expression profile of brain-derived EVs in blood may allow us to non-invasively assess miRNA dysregulation and thus to gain knowledge about the pathophysiology of psychiatric disorders and identify potential new predictive targets. We searched PubMed for all studies related to the effects of psychiatric medications on EV-miRNAs and identified 14 relevant articles. Taken together, findings indicate that certain EV-miRNAs may be targets for psychiatric medications and that antipsychotics such as olanzapine and antidepressants such as fluoxetine may alter the expression levels of particular EV-miRNAs. If confirmed and replicated, these findings may lead to the suggested miRNA profiles being used as pharmacodynamic biomarkers. However, heterogeneities and uncertainties remain regarding the role of EV-miRNAs in psychiatric disorders and their interaction with neuronal gene expression and drugs. This minireview summarizes some of the findings on the effects of psychiatric medications on EV-miRNAs and describes the potential role of EV-miRNAs as pharmacodynamic biomarkers for psychiatric disorders.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 62-68"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Placental epigenetic signatures of maternal distress in glucocorticoid-related genes and newborn outcomes: A study of Spanish primiparous women 糖皮质激素相关基因中孕产妇痛苦的胎盘表观遗传学特征与新生儿结局:对西班牙初产妇的研究。
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.001
Agueda Castro-Quintas , Helena Palma-Gudiel , Elisenda Eixarch , Nerea San Martín González , Simone Röh , Susann Sauer , Monika Rex-Haffner , Jose Luis Monteserin-Garcia , Lorena de la Fuente-Tomás , Fatima Crispi , Maria Paz Garcia Portilla , Elisabeth B. Binder , Lourdes Fañanas
{"title":"Placental epigenetic signatures of maternal distress in glucocorticoid-related genes and newborn outcomes: A study of Spanish primiparous women","authors":"Agueda Castro-Quintas ,&nbsp;Helena Palma-Gudiel ,&nbsp;Elisenda Eixarch ,&nbsp;Nerea San Martín González ,&nbsp;Simone Röh ,&nbsp;Susann Sauer ,&nbsp;Monika Rex-Haffner ,&nbsp;Jose Luis Monteserin-Garcia ,&nbsp;Lorena de la Fuente-Tomás ,&nbsp;Fatima Crispi ,&nbsp;Maria Paz Garcia Portilla ,&nbsp;Elisabeth B. Binder ,&nbsp;Lourdes Fañanas","doi":"10.1016/j.euroneuro.2024.10.001","DOIUrl":"10.1016/j.euroneuro.2024.10.001","url":null,"abstract":"<div><div>Maternal stress during pregnancy can impact offspring health, increasing the risk of neuropsychiatric disorders. The human placenta plays a crucial role in understanding this effect, influencing fetal programming as it connects maternal and fetal circulation. Our hypothesis centers on maternal stress influencing children's outcomes through placental DNA methylation, targeting three cortisol-regulating genes: <em>NR3C1, FKBP5</em>, and <em>HSD11B2</em>.</div><div>In this pilot study, chorionic villi and maternal decidua placental layers from 45 mother-infant dyads (divided into two groups based on high/low maternal stress exposure) were analyzed for DNA methylation at the genes of interest via targeted bisulfite sequencing. Pregnant women provided four saliva samples throughout a day for cortisol determinations and were assessed for the presence of depressive symptoms at each of the three trimesters of pregnancy. Newborns underwent neurodevelopmental assessments and salivary cortisol evaluations at 7 weeks.</div><div>Increased maternal diurnal cortisol levels in the first trimester of pregnancy was significantly associated with elevated DNA methylation at exon 1D of the <em>NR3C1</em> gene and lower DNA methylation at intron 7 of the <em>FKBP5</em> gene, both in chorionic villi samples. Elevated DNA methylation at introns 1 and 7 of <em>FKBP5</em> in the maternal decidua were strongly linked to an anticipated delivery. DNA methylation at the <em>HSD11B2</em> promoter region was uniformly low across all placental samples. No associations with newborn neurodevelopment were found.</div><div>These results emphasize the importance of exploring layer-specific methylation differences at distinct pregnancy stages, highlighting the complex interplay between maternal stress, placental epigenetic modifications, and fetal development throughout the prenatal period.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 36-47"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A meta-analysis of data-driven cognitive subgroups in bipolar disorder 双相情感障碍认知分组数据荟萃分析
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.008
E Bora
{"title":"A meta-analysis of data-driven cognitive subgroups in bipolar disorder","authors":"E Bora","doi":"10.1016/j.euroneuro.2024.10.008","DOIUrl":"10.1016/j.euroneuro.2024.10.008","url":null,"abstract":"<div><div>The delineation of cognitive subgroups of bipolar disorder (BD) might be helpful for identifying biologically valid subtypes of this disorder. This meta-analysis identified peer-reviewed literature on studies investigating cognitive subgroups of BD with data-driven clustering methods. Relevant studies were searched in PubMed, Scopus, and Web of Science. Random-effects meta-analysis was performed using R software. A total of 14 cross-sectional studies including euthymic or mildly symptomatic patients with BD were included in the current meta-analysis. The available studies have consistently supported a 3-cluster solution. The pooled prevalence of the severe-impairment, moderate-impairment, and major good-functioning groups were 23.1 % (95%CI, 18.5 %–27.7 %), 42.5 % (95%CI, 36.3 %–48.8 %), and 33.5 % (95%CI, 25.9 %–41.1 %) respectively. Compared to healthy controls, both the severe-impairment (g=−1.40 to −1.73) and moderate-impairment groups (g=−0.59 to −0.96) had significant deficits in all six cognitive domains (verbal memory, visual memory, executive functions, working memory, attention and processing speed). The good-performance subgroup had a small increase in the performance of executive functions (g=0.23) and normal functioning in all other domains. Compared to the good-performance subgroup, the severe-impairment subgroup was characterized by more severe functional impairment, more hospital admissions, a higher percentage of type I BD and antipsychotic use. The characteristics of the moderate-impairment subgroup were lying between the other two subgroups for most of the measures. The current findings support the existence of 3 cognitive subgroups in BD including severe-impairment and moderate-impairment groups which are associated with a more severe course of illness.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 48-57"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“The role of gut microbiota in adult attention deficit hyperactivity disorder: Insights and implications” "肠道微生物群在成人注意缺陷多动障碍中的作用:见解和影响"
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.09.008
Muhammad Hussnain Sadiq, Ayesha Fatima
{"title":"“The role of gut microbiota in adult attention deficit hyperactivity disorder: Insights and implications”","authors":"Muhammad Hussnain Sadiq,&nbsp;Ayesha Fatima","doi":"10.1016/j.euroneuro.2024.09.008","DOIUrl":"10.1016/j.euroneuro.2024.09.008","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 58-59"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lurasidone-related adverse events: A comprehensive analysis from the FAERs database in real-world settings 鲁拉西酮相关不良事件:从 FAERs 数据库中对真实世界环境进行综合分析
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-06 DOI: 10.1016/j.euroneuro.2024.10.010
Jiannan Zhu , Lu Hou , Qin Zhou , Rongrong Lu , Zhiqiang Du , Ying Jiang , Haohao Zhu
{"title":"Lurasidone-related adverse events: A comprehensive analysis from the FAERs database in real-world settings","authors":"Jiannan Zhu ,&nbsp;Lu Hou ,&nbsp;Qin Zhou ,&nbsp;Rongrong Lu ,&nbsp;Zhiqiang Du ,&nbsp;Ying Jiang ,&nbsp;Haohao Zhu","doi":"10.1016/j.euroneuro.2024.10.010","DOIUrl":"10.1016/j.euroneuro.2024.10.010","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 60-61"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area 口服一水肌酸对抑郁症认知行为疗法的疗效和安全性:在资源匮乏地区进行的为期 8 周的双盲、随机、安慰剂对照可行性和探索性试验。
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-01 DOI: 10.1016/j.euroneuro.2024.10.004
Nima Norbu Sherpa , Riccardo De Giorgi , Edoardo Giuseppe Ostinelli , Amrita Choudhury , Tenzin Dolma , Sangila Dorjee
{"title":"Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area","authors":"Nima Norbu Sherpa ,&nbsp;Riccardo De Giorgi ,&nbsp;Edoardo Giuseppe Ostinelli ,&nbsp;Amrita Choudhury ,&nbsp;Tenzin Dolma ,&nbsp;Sangila Dorjee","doi":"10.1016/j.euroneuro.2024.10.004","DOIUrl":"10.1016/j.euroneuro.2024.10.004","url":null,"abstract":"<div><div>Pre-clinical and clinical evidence proposes that creatine monohydrate, an affordable nutraceutical, could be a useful adjunct to conventional antidepressant treatments. In this pilot feasibility and exploratory study, we investigate the 8-week effects of creatine in addition to cognitive-behavioural therapy (CBT) versus placebo plus CBT in depression. For the primary efficacy outcome of change in Patient Health Questionnaire-9 depression score at study endpoint, we used mixed-model repeated measures analysis of covariance. Logistic regressions were employed to assess acceptability (any-cause dropouts), tolerability (dropouts for adverse events), and safety (patients experiencing one or more adverse events). We calculated effect sizes adjusted for age, sex, and baseline depression score. One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression (mean PHQ-9 = 17.6 ± 6.3) were randomised to either creatine+CBT (<em>N</em> = 50) or placebo+CBT (<em>N</em> = 50). At 8 weeks, PHQ-9 scores were lower in both study arms, but significantly more so in participants taking creatine (mean difference= -5.12). Treatment discontinuations due to any cause and to adverse events, and proportion of participants with at least one adverse event were comparable between study arms. This hypothesis-generating trial suggests that creatine could be a useful and safe supplement to CBT for depression. Longer and larger clinical trials are warranted.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 28-35"},"PeriodicalIF":6.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency 与 10 赫兹经颅磁刺激相比,18 赫兹深部经颅磁刺激是否能使不同亚组的抑郁症患者受益?个体阿尔法频率的作用
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-10-12 DOI: 10.1016/j.euroneuro.2024.09.007
Helena Voetterl , Uri Alyagon , Victoria J. Middleton , Jonathan Downar , Abraham Zangen , Alexander T. Sack , Hanneke van Dijk , Aimee Halloran , Nancy Donachie , Martijn Arns
{"title":"Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency","authors":"Helena Voetterl ,&nbsp;Uri Alyagon ,&nbsp;Victoria J. Middleton ,&nbsp;Jonathan Downar ,&nbsp;Abraham Zangen ,&nbsp;Alexander T. Sack ,&nbsp;Hanneke van Dijk ,&nbsp;Aimee Halloran ,&nbsp;Nancy Donachie ,&nbsp;Martijn Arns","doi":"10.1016/j.euroneuro.2024.09.007","DOIUrl":"10.1016/j.euroneuro.2024.09.007","url":null,"abstract":"<div><div>Both 10 Hz repetitive transcranial magnetic stimulation (rTMS) as well as 18 Hz deep TMS (dTMS) constitute effective, FDA-approved TMS treatment protocols for depression. However, not all patients experience sufficient symptom relief after either of these protocols. Biomarker-guided treatment stratification could aid in personalizing treatment and thereby enhancing improvement. An individual alpha frequency (iAF)-based EEG-biomarker, Brainmarker-I, can differentially stratify patients to depression treatments. For instance, an iAF close to 10 Hz was associated with better improvement to 10 Hz rTMS, possibly reflecting entrainment of endogenous oscillations to the stimulation frequency.</div><div>Accordingly, we examined whether 18 Hz dTMS would result in better improvement in individuals whose iAF lies around 9 Hz, a harmonic frequency of 18 Hz.</div><div>Curve fitting and regression analyses were conducted to assess the relation between iAF and improvement. For treatment stratification purposes, correlations with iAF-distance to 10 Hz compared 18 Hz dTMS (<em>N</em> = 114) to 10 Hz rTMS (<em>N</em> = 72).</div><div>We found a robust quadratic effect, indicating that patients with an iAF around 9 Hz exhibited least symptom improvement (r<sup>2</sup>=0.126, <em>p</em>&lt;.001). Improvement correlated positively with iAF-distance to 10 Hz (<em>p</em>=.003). A secondary analysis in 20 Hz figure-of-eight data confirmed this direction. A significant interaction of iAF-distance and stimulation frequency between 10 and 18 Hz datasets emerged (<em>p</em>=.026).</div><div>These results question entrainment of endogenous oscillations by their harmonic frequency for 18 Hz, and suggest that 10 Hz and 18 Hz TMS target different subgroups of depression patients. This study adds to iAF stratification, augmenting Brainmarker-I with alternative TMS protocols (18 Hz/20 Hz) for patients with a slower iAF, thereby broadening clinical applicability and relevance of the biomarker.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"89 ","pages":"Pages 73-81"},"PeriodicalIF":6.1,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142417138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COMBINING MENDELIAN RANDOMISATION WITH DEPRESSION TRAJECTORIES TO IDENTIFY DEVELOPMENTALLY SPECIFIC PREDICTORS OF CHANGE IN DEPRESSIVE SYMPTOMS 将 "泯灭随机法 "与抑郁轨迹相结合,确定抑郁症状变化的发育特异性预测因素
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-10-01 DOI: 10.1016/j.euroneuro.2024.08.092
Robyn Wootton , Richard Parker , Michael Lawton , Kate Tilling
{"title":"COMBINING MENDELIAN RANDOMISATION WITH DEPRESSION TRAJECTORIES TO IDENTIFY DEVELOPMENTALLY SPECIFIC PREDICTORS OF CHANGE IN DEPRESSIVE SYMPTOMS","authors":"Robyn Wootton ,&nbsp;Richard Parker ,&nbsp;Michael Lawton ,&nbsp;Kate Tilling","doi":"10.1016/j.euroneuro.2024.08.092","DOIUrl":"10.1016/j.euroneuro.2024.08.092","url":null,"abstract":"<div><div>Prevalence of depression is increasing, especially amongst adolescents and young adults, representing a key risk period where intervention is critical. When using Mendelian randomisation (MR) to identify causal risk factors for depression, estimates are limited to average lifetime effects, rather than being specific to developmental stages.</div><div><strong>Methods.</strong> We have combined trajectories of depressive symptoms with MR to identify developmentally specific risk factors. We used repeated measures of depressive symptoms (short Moods and Feelings Questionnaire) in the ALSPAC cohort, with 11 repeated assessments covering ages 9 to 27 years. First, we used a repeated measures multi-level model (MLM) to describe the average trajectory of depressive symptoms. Linear splines split by knot points were used to explain the non-linear pattern of growth. Second, we used latent class analysis to explore heterogeneity in depression trajectories. Third, we combined both trajectory models with genetic instruments for depression (positive control) and with modifiable risk factors for depression.</div><div>Our models included 44,611 repeated assessments of sMFQ from 6,422 unique individuals. Our best fitting MLM trajectory had three linear splines corresponding to puberty (9-14.5 years), adolescence (14.5-21 years) and early adulthood (21-27 years). Latent classes were stable low, decreasing, transient, increasing and stable high. Positive control genetic instrument for MDD predicted trajectories, most strongly membership into the increasing and stable high class. Genetic instruments for BMI and educational attainment were not associated with change in population average depressive symptoms at any of the different developmental stages nor with class membership. This could suggest no causal effects of these risk factors at these developmental stages, or low power.</div><div>We are continuing to develop our methods, test power and incorporate additional risk factors. We believe that combining outcome trajectories with MR analyses has wide ranging application to improve specificity of causal effects and recommendations for intervention development.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Page 38"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信